Amundi Hutchmed (China) LTD Transaction History

Amundi

$264 Billion
Q3 2024

A detailed history of Amundi transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Amundi holds 173,894 shares of HCM stock, worth $3.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

173,894

Previous 173,894 -0.0%

Holding current value

$3.02 Million

Previous $2.98 Million 14.18%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$16.36 - $21.78 $1.28 Million - $1.7 Million	-78,062 Reduced 30.98%	173,894 $2.98 Million
Q1 2024 May 15, 2024	BUY	$12.08 - $18.56 $1.41 Million - $2.17 Million	116,789 Added 86.4%	251,956 $4.23 Million
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $1.6 Million - $1.99 Million	98,266 Added 266.3%	135,167 $2.45 Million
Q4 2022 Feb 14, 2023	SELL	$7.65 - $15.51 $1.53 Million - $3.1 Million	-199,927 Reduced 84.42%	36,901 $545,000
Q3 2022 Nov 14, 2022	BUY	$8.63 - $15.52 $44,876 - $80,704	5,200 Added 2.24%	236,828 $2.2 Million
Q2 2022 Aug 15, 2022	SELL	$8.59 - $20.77 $981,012 - $2.37 Million	-114,204 Reduced 33.02%	231,628 $3.05 Million
Q1 2022 May 16, 2022	BUY	$15.52 - $35.65 $888,908 - $2.04 Million	57,275 Added 19.85%	345,832 $6.23 Million
Q4 2021 Feb 14, 2022	BUY	$28.89 - $35.33 $115,415 - $141,143	3,995 Added 1.4%	288,557 $9.09 Million
Q3 2021 Nov 15, 2021	SELL	$35.66 - $42.94 $188,570 - $227,066	-5,288 Reduced 1.82%	284,562 $10.4 Million
Q2 2021 Aug 16, 2021	BUY	$23.7 - $39.27 $6.87 Million - $11.4 Million	289,850 New	289,850 $11.4 Million

Others Institutions Holding HCM

# of Institutions

Shares Held

6.88M

Call Options Held

6.2K

Put Options Held

1.1K

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.01B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account